media – Page 176 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【EXPERT Q&A】Why aren’t prescription drugs so tightly regulated?

Drugdu.com expert’s response: The reasons for the relatively lax regulation of prescription drugs involve multiple aspects, mainly including the following points: Profit-driven: The demand for prescription drugs is large and the profits are substantial, which leads some pharmacies to take risks and illegally sell prescription drugs in pursuit of profits. In a market economy, the primary business objective of pharmacies is economic benefits, so they may overlook the strictness of prescription drug regulation. Inadequate supervision: In some regions, the supervision of pharmacies is insufficient, making it difficult to effectively curb violations. The limited availability of regulatory resources and the relatively lagging regulatory measures may create loopholes in the practical operation of prescription drug regulation. Lack of consumer awareness: Some consumers lack sufficient understanding of the definition and importance of prescription drugs, making them susceptible to诱导by pharmacies. This information asymmetry leaves consumers with inadequate judgment and vigilance when facing prescription drugs. ...
- Source: drugdu
- 501
- February 10, 2025
Analysis Report on Import and Export of Medical Devices in China

This report is based on the import and export data of China Customs, and conducts multidimensional analysis from the overall trend of medical device import and export, trade categories, trading partners, trading provinces and cities, aiming to objectively evaluate the trend and market pattern of China’s medical device import and export trade, and provide certain data references for relevant enterprise project evaluation, market research, channel expansion, etc. The relevant data are all sourced from the global medical device big data service platform – Yaozhi Medical Device Data, under the umbrella of Yaozhi Network. If you need detailed data in the report, please go to Yaozhi Medical Equipment Data for more information. Overall analysis Overall, compared to last year, China’s import and export trade volume has shown a comprehensive growth trend. From January to December 2024, overall data shows that in terms of exports, the Asian market is the largest export ...
- Source: drugdu
- 1,030
- February 7, 2025
Starting from February 1st, the settlement method for centralized procurement consumables has changed

Hunan will implement a new settlement method for centralized procurement consumables, with artificial crystals as the first batch of products. Starting from February 1st, the settlement method will be changed Recently, the Hunan Provincial Medical Security Bureau issued a notice on the direct settlement of medical insurance fund payments for selected medical consumables in centralized quantity procurement (hereinafter referred to as the “Notice”), requiring direct settlement of medical insurance fund payments for selected consumables products in centralized procurement to be carried out from February 1, 2025. The document on which the “Notice” is based is the “Notice on Implementing Direct Settlement of Medical Insurance Funds for Centralized Procurement of Selected Products’ Medical Payment” (Xiang Medical Insurance Fa [2023] No. 36). The Notice specifies that from February 1st, direct settlement of medical insurance funds for selected consumables products through centralized procurement will be carried out. The first batch of consumables selected ...
- Source: drugdu
- 321
- February 7, 2025
Haisike has been approved to conduct clinical trials of the innovative drug HSK39004

On February 5, Haisike (002653) issued an announcement that its subsidiaries Tibet Haisike Pharmaceutical Co., Ltd. and Sichuan Haisike Pharmaceutical Co., Ltd. recently received the “Notice of Approval for Drug Clinical Trials” issued by the State Drug Administration, approving the innovative drug HSK39004 inhalation powder spray developed by them to conduct clinical trials. The drug is mainly used to treat chronic obstructive pulmonary disease and meets the relevant requirements for drug registration. HSK39004 is a targeted small molecule inhibitor independently developed by the company. Preclinical studies have shown that it has significant effects on airway relaxation and anti-inflammation, and has good safety and great development potential. According to the drug registration classification regulations, the drug is classified as Class 1 chemical drug. Although the project has good prospects, the company also reminds investors that the research and development cycle of innovative drugs is long and the risk is high, and ...
- Source: drugdu
- 406
- February 7, 2025
Innovative drugs are expected to accelerate into hospitals, and the Class C medical insurance catalogue is about to be released

Follow the incremental policy and grasp the incremental rhythm. At this stage and for a long time in the future, innovative drugs are the most clear direction of incremental policy support. We continue to be optimistic about high-quality innovative pharmaceutical companies and transformation companies that have achieved results. Innovative drugs are expected to accelerate into hospitals, and the Class C medical insurance catalogue is about to be released. The new version of the medical insurance catalogue will be implemented from January 2025, and many newly included blockbuster innovative drugs will speed up their entry into hospitals under the promotion of the implementation details. The 2025 medical insurance negotiations will be reported in advance on April 1, and the medical insurance negotiations will end in September, which will help the newly approved products to be included in the medical insurance faster. The first version of the Class C catalog is expected ...
- Source: drugdu
- 470
- February 7, 2025
Keytruda sold $29.5 billion last year, and Merck suspended shipments of HPV vaccines to the Chinese market

On February 4, Merck announced its fourth quarter financial report for 2024 and its full-year performance last year. Of the $64.2 billion in sales for the year, its PD-1 monoclonal antibody product pembrolizumab (trade name Keytruda, commonly known as “Keytruda”) accounted for nearly half, with sales of $29.5 billion. Merck also announced that it would suspend shipments of HPV vaccine products Gardasil/Gardasil 9 to the Chinese market from February this year, and this decision will last at least until the middle of this year. Merck China said that this decision was mainly affected by the overall market environment, weak consumer demand and high channel inventory; it also maintains full confidence in the potential of the Chinese market. Suspending shipments to the Chinese market from this month At the same time as announcing its financial report, Merck announced a highly anticipated decision, namely, from February this year, it will suspend shipments ...
- Source: drugdu
- 334
- February 7, 2025
The application for marketing authorization of the independently developed drug of the holding subsidiary was approved by the EU

On February 5, Fosun Pharma announced that the marketing authorization application (MAA) of slulizumab injection (i.e., anti-PD-1 monoclonal antibody) independently developed by the holding subsidiary Shanghai Fuhong Henlius Biotech Co., Ltd. and its holding subsidiaries (collectively referred to as “Fuhong Henlius”) for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) was recently approved by the European Commission (i.e., the European Commission). Accordingly, the drug has obtained centralized marketing authorization in all EU member states and Iceland, Liechtenstein and Norway (European Economic Area countries respectively), and has become the first anti-PD-1 monoclonal antibody approved by the EU for the treatment of extensive-stage small cell lung cancer (ES-SCLC). https://finance.eastmoney.com/a/202502063311927270.html
- Source: drugdu
- 319
- February 7, 2025
【EXPERT Q&A】What are the differences between generic drugs and original drugs?

Drugdu.com expert’s response: Detailed Comparison Between Generic Drugs and Originator Drugs I. Definition and Background Originator Drugs: These are innovative drugs that are originally researched and developed by companies that hold the patent rights for the medication. These new drugs typically undergo long-term safety evaluations and complete Phase I to III (and sometimes Phase IV) clinical trials, followed by continuous post-marketing monitoring of their efficacy. The research and development (R&D) of originator drugs are usually initiated by large, financially strong pharmaceutical companies, taking up to fifteen years from R&D to market launch, with costs reaching billions of dollars. Generic Drugs: These are drugs that are developed after the patent protection period (typically 20 years) of an originator drug expires, based on research into the main active ingredient of the originator drug. The R&D process for generic drugs is relatively straightforward, involving the replication of the main molecular structure of the ...
- Source: drugdu
- 848
- February 7, 2025
Nepal launches national HPV vaccination program, expected to benefit more than 1.68 million girls

The Nepali government officially launched the HPV vaccination program nationwide on the 4th, and it is expected to vaccinate more than 1.68 million girls aged 10 to 14 to prevent cervical cancer and other related diseases. Nepali Prime Minister Oli attended the launch ceremony in the capital Kathmandu on the same day and presented vaccination materials to health workers. The vaccination program is led by the Ministry of Health and Population of Nepal and supported by the Global Vaccine Alliance (GAVI). It will be carried out nationwide from February 4 to 18, 2025. It is reported that a total of 18,900 schools in Nepal have been designated as vaccination centers, and another 8,200 medical institutions will provide vaccination services to the public. The Ministry of Health and Population of Nepal said that cervical cancer is the second most common cancer among women in Nepal and the leading cause of cancer ...
- Source: drugdu
- 365
- February 6, 2025
Uganda launches vaccine trial for Sudan Ebola virus

Kampala, February 4: Uganda’s Ministry of Health, the World Health Organization and other partners launched the world’s first vaccine trial for Sudan Ebola virus on February 3 local time. On January 30 local time, the Ugandan Ministry of Health announced that the country had an Ebola outbreak again after a lapse of two years, and a nurse in the capital Kampala died of Ebola virus infection. A statement issued by the WHO said that after the outbreak, Uganda’s local leading researchers prepared for the trial within 4 days with the support of the WHO and other partners. This is the first clinical efficacy trial of a vaccine against Sudan Ebola virus. Reuters reported that the trial will mainly target contacts of confirmed cases. According to the Associated Press, on February 3, two more relatives of the deceased nurse were confirmed to be infected with Ebola virus. The Ugandan government is ...
- Source: drugdu
- 247
- February 6, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.